Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
复制标题
1-(2-羟基乙氧基)甲基-2-烷基-3-羟基-4-吡啶酮的无环核苷铁螯合剂：潜在的口服铁螯合疗法。
DOI：
10.1081/ncn-120030718
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
Bruenger,FredW
中科院分区：
文献类型：
--
作者：
Liu,Gang;Men,Ping;Kenner,GerryH;Miller,ScottC;Bruenger,FredW
与合成核糖核苷铁螯合剂的方法相比，合成无环核苷铁螯合剂既方便又经济。X射线晶体结构分析表明，2 -羟基乙氧基不影响铁螯合位点的几何形状。因此，无环核苷铁螯合剂的铁结合和去除性能应该与核糖核苷铁螯合剂相似，这一点分别由无环核苷铁螯合剂与铁和铁蛋白的滴定和竞争反应得到证实。通过测量正辛醇和Tris缓冲液分布系数，无环核苷铁螯合剂比核糖核苷铁螯合剂亲脂性更强。
The method of synthesizing acyclonucleoside iron chelators is both convenient and cost effective compared to that of synthesizing ribonucleoside iron chelators. The X‐ray crystal structural analysis shows that the 2‐hydroxyethoxymethyl group does not affect the geometry of the iron chelating sites. Therefore, the iron binding and removal properties of the acyclonucleoside iron chelators should remain similar to the ribonucleoside iron chelators, which is confirmed by the titration and competition reaction of the acyclonucleoside chelators with iron and ferritin, respectively. The acyclonucleoside iron chelators are more lipophilic with measured n‐octanol and Tris buffer distribution coefficients than ribonucleoside iron chelators.